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New oral anticoagulants (NOAC) are approved for several indications for prophylaxis and treatment of venous
thromboembolism and for prevention of embolism in atrial fibrillation at fixed daily doses without need of
laboratory guided dose adjustment. Due to their low molecular weight of about 500 to 600 Dalton and their
hydrophilicity free anticoagulant is excreted immediately through glomerular filtration into the urine. Impairment of
renal function may increase the plasma concentration of the anticoagulants and lowered creatinine clearance is a
declared contraindication. In contrast to the initial aim of development the anticoagulant effect is required to be
determined in special clinical situations. Several specific and non-specific assays using plasma samples are currently
undergoing standardization. As all NOACs are excreted into the urine, specific assays were developed for this matrix
to determine them quantitatively of qualitatively. Urine samples can be easily and repetitively obtained avoiding
problems and risks associated with blood sampling. The qualitative assay can be performed as a point of care test
(POC) also by the patient by judging the different colours for the absence or presence of the drugs with the naked
eye. The test is rapid (results available within 15 min), sensitive, specific and accurate and does not require a
purified NOAC as control. The tests may be a tool for clinicians who need to know for treatment decisions if a
NOAC is on board or not. As the tests are specific for oral direct thrombin inhibitors and for oral direct factor Xa
inhibitors, the indication does not interfere with other qualitative POC test in development using clotting systems.
The test may be indicated for patients at acute hospitalization, before surgery or central nervous system puncture
anaesthesia, if fibrinolytic therapy is indicated, acute deterioration of renal function, and for control of adherence
to therapy.
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Thromboembolic complications are one of the major
complications following primary elective total hip (THR)
and knee replacement (TKR) surgery with considerable
morbidity and mortality, which can be reduced substan-
tially by subcutaneous low-molecular weight heparins
and new oral anticoagulants [1]. Cerebral and non-
cerebral embolism is the most relevant severe event
occurring in patients non-valvular atrial fibrillation (AF)
which can be effectively prevented by vitamin-K antago-
nists (VKA) [2]. Limitations of the conventional regimes
for prophylaxis of venous thromboembolism (VTE) with* Correspondence: job.harenberg@medmam.uni-heidelberg.de
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distribution, and reproduction in any mediumlow molecular weight heparin (LMWH) include local
haematoma and allergy, heparin-induced thrombocyto-
penia type I and type II, transient increase of liver enzy-
mes, and the requirement for parenteral administration
[3]. VKA requires frequent dose adjustments to obtain the
time in the therapeutic range of international normalized
ratio (INR) values between 2 and 3 [4]. Many interactions
with food and drugs, the slow onset and offset of action of
VKAs require simultaneous administration of UFHs or
LMWHs in many clinical situations. Severe intracranial
and extracranial bleeding complications and other severe
side effects also limit the administration of VKA. The
underuse of vitamin-K antagonists is one of the conse-
quences of the fear of bleeding complications especially in
older [5]. One option to improve the efficacy and safety of
treatment with VKA is to adopt point-of-care whole bloodtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Clinical situations where determination of NOACs
may be required
• Before surgery, lumbar anesthesia
• At any hospitalization
• Any bleeding/haemorrhage
• Any thrombotic and embolic event
• Indication for thrombolytic therapy
• Suspicion of deterioration of renal function
• Dehydration / exsiccation
• Newly diagnosed pregnancy
• Very elderly
• Children
• Adherence to therapy /compliance
• Suspicion of intoxication
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ever, this option is limited to a small group of patients able
to follow the instruction of the POC device and restricted
by the unwillingness of health insurance systems to cover
the additional expenses [9]. To improve and facilitate oral
anticoagulant therapy small molecular orally available
anticoagulants (NOAC) specifically inhibiting factor Xa or
thrombin were developed and some of them are now
approved for several indications.
NOAC do not require routine drug monitoring to
adjust the dose because they have a relatively low variation
of their pharmacological profile after administration in
man. Because all NOACs are small molecules with a mo-
lecular weight of about 500 to 600 dalton, renal function
plays a major role for the metabolism ranging from 80%
for the direct thrombin inhibitor dabigatran to about 33%
for factor Xa inhibitors rivaroxaban [10] and 25% for
apixaban. Accordingly, reduction of creatinine clearance
to less than 30 ml/min for dabigatran or 15 ml/min for
rivaroxaban and apixaban are regarded as a contraindi-
cation for treatment. The dose of dabigatran has to be
reduced by about 30% according to the European
guidelines and by 50% according to the food and drug
administration guidelines for creatinine clearance bet-
ween 50 and 30 ml/min, and the doses of rivaroxaban
and apixaban by 50% for creatinine clearances between
30 and 15 ml/min.
The concentration of NOACs can be accurately deter-
mined by high-pressure liquid chromatography methods.
These techniques are, however, unsuitable for clinical
routine use. Thrombin and factor Xa dependent coagu-
lation or chromogenic substrate assays have therefore
been developed to respectively determine the concentra-
tion or activity of dabigatran and rivaroxaban [11,12].
However, point of care (POC) methods to determine
NOACs have not been reported so far. Measurement of
anticoagulants in urine has been reported previously by the
authors for heparin [13], a modified heparin derivative
[14], r-hirudin and its pegylated derivative [15], metabolites
of phenprocoumon [16] and of fibrinopeptide A, which is
a split product of fibrinogen upon action of thrombin [17].
Advantages of urine sampling include the non-invasive
techniques and the possibility to develop POC test sys-
tems. These assays can be performed by trained personal
or by the patients themselves, and can be repeated easily
[18,19].
Indications for determination of NOACs
In specific clinical situations determination of NAOCs
may be required for clinical decision making. Typical
examples, where it is necessary to know if the drug is on
board or not, are indication for fibrinolytic therapy in
cerebral embolism, placement of a lumbar catheter, and
severe bleeding events.Renal function reduces with increasing age. Many
diseases do or may reduce renal function independently
of age. Therefore, renal elimination of NOACs is redu-
ced in various clinical conditions (Table 1).
Rationale of the POC test from urine
Development of point of care (POC) methods for NOACs
in urine is based on their immediate glomerular filtration
and excretion into the urine when they are present in
blood. This concept was used to develop specific POC
methods for oral direct factor Xa inhibitors and oral direct
thrombin inhibitors.
Methods
The test principle is based on the development of differ-
ent colours in the presence and absence of oral direct
factor Xa and thrombin inhibitors. The details of the
methods are described in the patent applications for direct
thrombin inhibitors [20] and direct factor Xa inhibitors
[21]. For a POC testing it becomes important that the col-
ours are read correctly by the naked eye. Mistakes should
not occur for identification of the colours. This has been
taken into consideration for the development of the test
systems. Accordingly, colours for negative and positive
were chosen with a contrast high enough to differenti-
ate between presence and absence of the NOAC. Im-
portantly, colour for factor Xa and thrombin inhibitors
had to be different to avoid a confounding of two clas-
ses of inhibitors. Two colours were chosen for each
class of inhibitors: for factor Xa (absence: yellow colour,
present: clear colour, Figure 1) and thrombin inhibitors
(absence: green colour, present: blue colour, Figure 2)
are different.
As described [19], dabigatran was incubated with
ministrips containing lyophilized reagents followed by
incubation with patient’s urine [20]. The initially blue
Figure 1 Results of the POC test with urine of a patient not on
treatment with dabigatran (left, blue colour) and on treatment
with dabigatran (right, green colour).
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absence of dabigatran within 15 minutes.
In detail [19], rivaroxaban was determined by a POC
method incubating the lyophilized reagents on strips
followed by incubation with patient’s urine over 15 min
[21]. The yellow colour of the urine itself is diluted with
the reagents to a transparent solution. If the urine does
not contain rivaroxaban, a yellow colour develops during
incubation with the reagents immobilized on the strips.
If the urine contains rivaroxaban no colour develops and
the solution remains clear.
Results
The test results of the determination of dabigatran and
rivaroxaban are shown in Figures 1 and 2. To determine
the correctness of identifying the colours by patientsFigure 2 Results of the POC test with urine of a patient not on
treatment with rivaroxaban (left, transparent colour) and on
treatment with rivaroxaban (right, yellow, no colour).with the naked eye, positive and negative samples for
dabigatran and rivaroxaban were prepared and were read
by patients [19]. The results of the sensitivity, specificity,
accuracy, positive and negative predictive indices are
given in Table 2.
The results show that the values are somewhat higher
with the dabigatran test using green and blue colours.
The results with rivaroxaban a little bit worse, but still
very high with values for sensitivity, specificity and
accuracy all above 95%. Importantly, the yellow colour
of normal urine is diluted in the test procedure and do
not influence the results. However, if a urine sample is
very concentrated the dilution of the yellow colour may
not be sufficient and may lead to intermediate colour
which cannot be clearly adjudicated as transparent or
yellow. Detailed results of the POC method in urine
were published earlier [18,19].Discussion
In certain clinical situation may require the determin-
ation of their anticoagulant effect. These situations may
occur more frequently in acute than in chronic situa-
tions. POCT methods are available and are successfully
used for determination of the INR during treatment with
VKA. At present, the TP reagents used for the currently
available POCT monitors are not sensitive towards
rivaroxaban or dabigatran (unpublished data). In chronic
therapy adherence to drug treatment was shown to in-
crease by using POCT methods [22]. POCT methods
from urine samples have been reported for several drugs
[23], and have shown to improve adherence to therapy
[24]. Urine samples are easy to collect and are commonly
used to control adherence to drug therapy. Samples can
be collected by the patient and any health care personal. If
samples are analysed by a POCT system, results are avail-
able within minutes. The strength of the methods is that
they are not invasive, repetitively to perform, that results
are available within 15 min, that patients can perform theTable 2 Results of the sensitivity, specificity, accuracy,
positive predictive value, and negative predicted value of
the POC test from urine samples of patients treated with
dabigatran or rivaroxaban
Dabigatran N=484 Rivaroxaban N=457
Mean 95% CI Mean 95% CI
Sensitivity 100 99–100 96 94–98
Specificity 99 98–100 98 96–99
Accuracy 99 99–100 97 96–98
PPI 99 98–100 98 97–99
NPI 100 99–100 96 94–98
PPI positive predictive index, NPI negative predictive index. Results of patients
not on treatment with anticoagulants served as control (adapted from 19).
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control. The methods are sensitive, specific, accurate and
posses a very high inter-rater agreement [19].
Limitations of the test system for both test system are,
that they become negative if renal impairment is
reduced to more than 10 ml/min creatinine clearance.
This value may be more relevant for dabigatran than the
oral direct factor Xa inhibitors because of the higher
elimination rate into the urine. A limitation of the test
for dabigatran exists for patients with a red-green
amblypoia. Relatives or other persons have to perform
the test. A limitation for the oral direct factor Xa inhibi-
tor test is that concentrated urine may produce a yellow
colour. To avoid such misinterpretation, a scale with
colours of native urine has to be added to the test
system indication that the testing is possible or not
possible.
Other limitations of the POC methods include the lack
of information about the compliance of the patient.
Patients may not have taken the last dose of the NOAC
before blood collection and urinary excretion may still
continue. This is particularly essential for emergency
physicians, who should be aware on how to interpret re-
sults. However, acute urine samples can be repetitively
obtained in emergency situations to cover this problem.
In conclusion, determination of dabigatran, rivaro-
xaban and other direct factor Xa inhibitors from urine
using POC methods are characterized by a high sensiti-
vity, specificity, and accuracy. The POC methods are
non-invasive, easy to perform and can be done repe-
titively. The use in real world situations remains to be
investigated [19].Competing interests
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